Summary Information:
Decibel Therapeutics Inc. Common Stock
NASDAQ:DBTX


email
admin@troach.net
Our Main Pages
Stocks.TRoach.Net
TRoach.Org
TRoach.Net

NOTE: This page is for evaluation of a JFF Project.
This page is NOT updated on a regular basis.
Information on this page should NOT be used for investment purposes.


Decibel Therapeutics Inc. Common Stock
Exchange: NASDAQ
Symbol: DBTX
SEC CIK: 0001656536
Phone: 617-370-8701
1325 BOYLSTON STREET
SUITE 500
BOSTON MA 02215
CEO:
Price when page updated: 5.12 Date: 2023-09-10
Company Website:
www.decibeltx.com

_Description: Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all.

IPO YEAR:
2021
Sector:
Health Care
Industry:
Biotechnology: Pharmaceutical Preparations
ADRTSO:

MarketCap:
128649907.00
Beta:

52 Week High:
24.39
52 Week Low:
4.5
52 Week Change:
-0.7459789240155297
Short Interest:

Short Date:

Shares Outstanding:
24923363
Dividend Rate:
0
Dividend Yield:
N/A
ExDividend Date:

Latest EPS:

Latest EPS Date:
13 Oct 2022
Float:
0
return on Equity:
-50.60%
Consensus EPS:

Number Of Estimates:

EPS Surprise Dollar:

Eps Surprise Percent:

EBITDA:
N/A
ttmEPS:
0
Revenue:
$18.871M
Gross Profit:

Cash:

Debt:

Institution Percent:
18.10%
Revenue Percent:

Revenue Per Employee:

Insider Percent:
14.96%
Return on Assets:
-32.80%
Return on Capital:

Profit Margin:
-24.00%
Price to Sales:
2.87
Price To Book:
6.12
Short Ratio:
1.06
PE Ratio:
0
Employees:
40
1Y Guesstimate
N/A:N/A:N/A




__The following are links to various summary and news pages for
__Decibel Therapeutics Inc. Common Stock [ DBTX ].

__Note: Some Links might not have information for the company.


finance.Yahoo.com money.CNN.com NASDAQ research
WalletInvestor.com WSJ.com MarketBeat.com
finviz.com WallMine.com TheGlobeandMail.com
stock1010.com
NASDAQ - General Info SEC Insider Report Ownership Summary
Dividend History insiderbuyingselling.com
Facebook search Twitter search LinkedIn search
PRnewsWire.Com Google Forecast
tdameritrade.com BarChart.com
SeekingAlpha.com Markets.FT.com stocktwits.com
FinTel.io Ldmicro.com bloomberg.com
MarketWatch.com Reuters.com businessinsider.com
fool.com barrons.com zacks.com
GuruFocus.com Investing.com tipranks.com
thestreet.com nytimes.com earningswhispers.com
marketchameleon.com sunshineavenue.com stockinvest.us
stockanalysis.com stockconsultant.com ycharts.com
financialcontent.com docoh.com foxbusiness.com
cnbc.com investorsobserver.com tradingview.com
investopedia.com tmxmoney.com invest.cnyes.com
ask.com bing.com brave.com
duckduckgo.com ecosia.org excite.com
exalead.com gibiru.com hotbot.com
www.info.com infospace.com lycos.com
lukol.com metacrawler.com mojeek.com
becovi.com searx.thegpm.org search.com
swisscows.com webcrawler.com yahoo.com
yandex.com yep.com you.com




INDEX




Page design by: TRoach
Page Last Updated: 2023-09-10